Yu-Ying Liu Selected Research

notoginsenoside R1

1/2021	The Composite of 3, 4-Dihydroxyl-Phenyl Lactic Acid and Notoginsenoside R1 Attenuates Myocardial Ischemia and Reperfusion Injury Through Regulating Mitochondrial Respiratory Chain.
7/2015	QiShenYiQi Pills, a compound in Chinese medicine, protects against pressure overload-induced cardiac hypertrophy through a multi-component and multi-target mode.
1/2014	Protective effects of Notoginsenoside R1 on intestinal ischemia-reperfusion injury in rats.
1/2008	Effect of notoginsenoside R1 on hepatic microcirculation disturbance induced by gut ischemia and reperfusion.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Yu-Ying Liu Research Topics

Disease

20	Ischemia 06/2022 - 01/2008
12	Edema (Dropsy) 06/2022 - 04/2012
10	Reperfusion Injury 01/2021 - 08/2009
7	Neoplasms (Cancer) 01/2022 - 01/2006
4	Infections 06/2022 - 01/2016
4	Fibrosis (Cirrhosis) 01/2019 - 06/2008
4	Cardiovascular Diseases (Cardiovascular Disease) 01/2019 - 04/2010
4	Brain Edema (Cerebral Edema) 01/2018 - 04/2012
4	Ischemic Stroke 01/2018 - 10/2012
4	Lung Injury 01/2018 - 03/2013
4	Body Weight (Weight, Body) 06/2017 - 05/2011
3	Myocardial Ischemia (Ischemic Heart Diseases) 01/2021 - 01/2018
3	Hemorrhage 01/2018 - 05/2011
3	Myocardial Infarction 01/2018 - 04/2010
3	Non-alcoholic Fatty Liver Disease 08/2017 - 06/2013
3	Thrombosis (Thrombus) 09/2015 - 01/2006
2	Rupture 01/2021 - 09/2013
2	Hypoxia (Hypoxemia) 01/2020 - 01/2018
2	Neoplasm Metastasis (Metastasis) 12/2019 - 02/2012
2	Endotoxemia 01/2019 - 10/2013
2	Type 2 Diabetes Mellitus (MODY) 01/2018 - 12/2007
2	Hyperlipidemias (Hyperlipidemia) 01/2018 - 01/2008
2	Cognitive Dysfunction 01/2018 - 01/2018
2	Fatty Liver 08/2017 - 06/2013
2	Respiratory Tract Diseases (Respiratory Tract Disease) 01/2017 - 10/2014
2	Colitis 01/2017 - 01/2013
2	Acute Lung Injury 12/2016 - 11/2014
2	Cerebral Infarction 01/2016 - 06/2015
2	Cardiomegaly (Heart Hypertrophy) 07/2015 - 01/2012
2	Brain Ischemia (Cerebral Ischemia) 06/2015 - 10/2012
2	Insulin Resistance 01/2015 - 12/2007
2	Infarction (Infarctions) 10/2012 - 04/2010
2	Glucose Intolerance 12/2007 - 09/2003

Drug/Important Bio-Agent (IBA)

10	AlbuminsIBA 06/2022 - 04/2012
10	Proteins (Proteins, Gene)FDA Link 06/2022 - 04/2010
7	qishen yiqiIBA 01/2021 - 01/2012
7	Evans Blue (Blue, Evans)FDA Link 01/2019 - 04/2012
6	Adenosine Triphosphate (ATP)IBA 06/2022 - 01/2013
5	Claudin-5IBA 01/2021 - 10/2012
5	AntioxidantsIBA 01/2019 - 01/2009
5	Adenosine Monophosphate (AMP)IBA 01/2018 - 01/2013
5	Cardiotonic Agents (Cardiac Stimulants)IBA 01/2013 - 01/2006
4	astragaloside AIBA 06/2022 - 11/2013
4	Lactic Acid (Lactate)FDA LinkGeneric 01/2021 - 01/2009
4	notoginsenoside R1IBA 01/2021 - 01/2008
4	LipopolysaccharidesIBA 01/2019 - 02/2014
4	CytokinesIBA 01/2018 - 10/2014
4	Adenosine Diphosphate (ADP)IBA 01/2018 - 09/2013
4	CollagenIBA 01/2018 - 01/2012
4	Pharmaceutical PreparationsIBA 01/2018 - 01/2008
4	VaccinesIBA 06/2017 - 06/2008
3	yi-qi-fu-maiIBA 01/2021 - 09/2009
3	Caveolin 1IBA 01/2021 - 10/2012
3	SirtuinsIBA 01/2021 - 08/2015
3	Sirtuin 3IBA 01/2019 - 08/2015
3	salvianolic acidIBA 01/2019 - 11/2010
3	src-Family KinasesIBA 01/2018 - 06/2015
3	OccludinIBA 01/2018 - 10/2012
3	Insulin (Novolin)FDA Link 01/2018 - 12/2007
3	NADPH Oxidases (NAD(P)H oxidase)IBA 01/2017 - 01/2013
3	caffeic acidIBA 09/2015 - 04/2012
2	Biomarkers (Surrogate Marker)IBA 01/2022 - 11/2019
2	Actins (F Actin)IBA 01/2021 - 01/2018
2	AntigensIBA 11/2019 - 06/2017
2	Blood Glucose (Blood Sugar)IBA 01/2018 - 12/2007
2	oxidized low density lipoproteinIBA 01/2018 - 12/2007
2	Laminin (Merosin)IBA 01/2018 - 12/2016
2	cadherin 5IBA 01/2018 - 01/2017
2	Silybin (Lagosa)IBA 01/2018 - 08/2017
2	Triglycerides (Triacylglycerol)IBA 08/2017 - 12/2007
2	Tight Junction ProteinsIBA 01/2017 - 10/2012
2	Sulfonic AcidsIBA 01/2017 - 01/2013
2	sym-trinitrobenzeneIBA 01/2017 - 01/2013
2	Therapeutic UsesIBA 01/2017 - 10/2012
2	Coloring Agents (Dyes)IBA 06/2013 - 04/2012
2	LipidsIBA 06/2013 - 12/2007
2	salvianolic acid BIBA 03/2013 - 01/2009
2	Caspase 3 (Caspase-3)IBA 04/2012 - 04/2010
2	DNA Nucleotidylexotransferase (Terminal Deoxynucleotidyl Transferase)IBA 04/2012 - 04/2010
2	Intercellular Adhesion Molecule-1 (Intercellular Adhesion Molecule 1)IBA 05/2011 - 04/2010
2	Glucose (Dextrose)FDA LinkGeneric 12/2007 - 09/2003
2	Trinitrotoluene (TNT)IBA 03/2006 - 07/2005
1	Small Interfering RNA (siRNA)IBA 06/2022
1	EnzymesIBA 01/2022
1	Chondroitin Sulfates (Chondroitin Sulfate)IBA 01/2022
1	ChondroitinIBA 01/2022
1	Carcinoembryonic AntigenIBA 02/2021
1	GoldIBA 02/2021
1	Tumor Biomarkers (Tumor Markers)IBA 02/2021
1	DNA (Deoxyribonucleic Acid)IBA 02/2021
1	Cell-Free Nucleic AcidsIBA 02/2021
1	oligomycin sensitivity-conferring protein (complex V)IBA 01/2021
1	Electron Transport Complex I (NADH-CoQ Reductase)IBA 01/2021

Therapy/Procedure

6	Therapeutics 12/2019 - 10/2012
5	Chinese Traditional Medicine (Traditional Chinese Medicine) 01/2018 - 01/2008
2	Drug Therapy (Chemotherapy) 12/2019 - 10/2016
2	Radiotherapy 12/2019 - 05/2007
2	Immunotherapy 11/2019 - 01/2019
2	Lasers (Laser) 01/2013 - 01/2012
2	Aftercare (After-Treatment) 12/2007 - 05/2007